These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 18358605)
41. Observation of multiple intermediates in alpha-synuclein fibril formation by singular value decomposition analysis. Kamiyoshihara T; Kojima M; Uéda K; Tashiro M; Shimotakahara S Biochem Biophys Res Commun; 2007 Apr; 355(2):398-403. PubMed ID: 17300751 [TBL] [Abstract][Full Text] [Related]
42. A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. Madine J; Doig AJ; Middleton DA Biochemistry; 2006 May; 45(18):5783-92. PubMed ID: 16669622 [TBL] [Abstract][Full Text] [Related]
43. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. Mishizen-Eberz AJ; Guttmann RP; Giasson BI; Day GA; Hodara R; Ischiropoulos H; Lee VM; Trojanowski JQ; Lynch DR J Neurochem; 2003 Aug; 86(4):836-47. PubMed ID: 12887682 [TBL] [Abstract][Full Text] [Related]
44. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575 [TBL] [Abstract][Full Text] [Related]
45. Products of Cu(II)-catalyzed oxidation of the N-terminal fragments of alpha-synuclein in the presence of hydrogen peroxide. Kowalik-Jankowska T; Rajewska A; Jankowska E; Wiśniewska K; Grzonka Z J Inorg Biochem; 2006 Oct; 100(10):1623-31. PubMed ID: 16839607 [TBL] [Abstract][Full Text] [Related]
47. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease. Kumar S; Sarkar A; Sundar D Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781 [TBL] [Abstract][Full Text] [Related]
48. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459 [TBL] [Abstract][Full Text] [Related]
49. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein. Heise H; Celej MS; Becker S; Riedel D; Pelah A; Kumar A; Jovin TM; Baldus M J Mol Biol; 2008 Jul; 380(3):444-50. PubMed ID: 18539297 [TBL] [Abstract][Full Text] [Related]
50. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Schell H; Hasegawa T; Neumann M; Kahle PJ Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424 [TBL] [Abstract][Full Text] [Related]
51. Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. Danzer KM; Krebs SK; Wolff M; Birk G; Hengerer B J Neurochem; 2009 Oct; 111(1):192-203. PubMed ID: 19686384 [TBL] [Abstract][Full Text] [Related]
52. Resistance of naturally secreted α-synuclein to proteolysis. Ximerakis M; Pampalakis G; Roumeliotis TI; Sykioti VS; Garbis SD; Stefanis L; Sotiropoulou G; Vekrellis K FASEB J; 2014 Jul; 28(7):3146-58. PubMed ID: 24723692 [TBL] [Abstract][Full Text] [Related]
53. In vitro phosphorylation does not influence the aggregation kinetics of WT α-synuclein in contrast to its phosphorylation mutants. Schreurs S; Gerard M; Derua R; Waelkens E; Taymans JM; Baekelandt V; Engelborghs Y Int J Mol Sci; 2014 Jan; 15(1):1040-67. PubMed ID: 24434619 [TBL] [Abstract][Full Text] [Related]
54. Binding of Cu(II) to human alpha-synucleins: comparison of wild type and the point mutations associated with the familial Parkinson's disease. Hong L; Simon JD J Phys Chem B; 2009 Jul; 113(28):9551-61. PubMed ID: 19548659 [TBL] [Abstract][Full Text] [Related]
55. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420 [TBL] [Abstract][Full Text] [Related]
56. Facile "stop codon" method reveals elevated neuronal toxicity by discrete S87p-α-synuclein oligomers. Ha Y; Yang A; Lee S; Kim K; Liew H; Suh YH; Park HS; Churchill DG Biochem Biophys Res Commun; 2014 Jan; 443(3):1085-91. PubMed ID: 24380864 [TBL] [Abstract][Full Text] [Related]
57. Site-specific fluorescence dynamics of α-synuclein fibrils using time-resolved fluorescence studies: effect of familial Parkinson's disease-associated mutations. Sahay S; Anoop A; Krishnamoorthy G; Maji SK Biochemistry; 2014 Feb; 53(5):807-9. PubMed ID: 24450731 [TBL] [Abstract][Full Text] [Related]
58. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Martinez Z; Zhu M; Han S; Fink AL Biochemistry; 2007 Feb; 46(7):1868-77. PubMed ID: 17253773 [TBL] [Abstract][Full Text] [Related]
59. beta-Sheet-breaking peptides inhibit the fibrillation of human alpha-synuclein. Kim YS; Lim D; Kim JY; Kang SJ; Kim YH; Im H Biochem Biophys Res Commun; 2009 Oct; 387(4):682-7. PubMed ID: 19622344 [TBL] [Abstract][Full Text] [Related]
60. Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage. Nakai M; Fujita M; Waragai M; Sugama S; Wei J; Akatsu H; Ohtaka-Maruyama C; Okado H; Hashimoto M Biochem Biophys Res Commun; 2007 Jun; 358(1):104-10. PubMed ID: 17475220 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]